Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL681120 | 1.00 | ALDH1A1 (0.37) | ALDH1A1LMNAKDM4EPOLBMEN1 | |
| SCHEMBL10248897 | 1.00 | ALDH1A1 (0.37) | ALDH1A1LMNAKDM4EPOLBMEN1 | |
| SCHEMBL10220842 | 0.93 | KDM4E (0.34) | ALDH1A1LMNAKDM4EPOLBMEN1 | |
| SCHEMBL20748223 | 0.93 | KDM4E (0.34) | ALDH1A1LMNAKDM4EPOLBMEN1 | |
| SCHEMBL20748224 | 0.93 | KDM4E (0.34) | ALDH1A1LMNAKDM4EPOLBMEN1 | |
| SCHEMBL679606 | 0.85 | ATM (0.34) | ATM | |
| SCHEMBL681239 | 0.85 | ATM (0.34) | ATM | |
| SCHEMBL681525 | 0.85 | ATM (0.34) | ATM | |
| SCHEMBL12359964 | 0.82 | ALDH1A1 (0.35) | ALDH1A1LMNAKDM4EPOLBMEN1 | |
| SCHEMBL10221054 | 0.81 | ACHE (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067656-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-02-29 | — | — | US | disclosed |
| US-11857603-B2 | PTH compounds with low peak-to-trough ratios | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2024-01-02 | — | — | US | disclosed |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230248730-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | PHARMACYCLICS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| US-20230248730-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | PHARMACYCLICS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| US-11718630-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718630-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230242544-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-11672803-B2 | Use of inhibitors of Brutons tyrosine kinase (Btk) | PHARMACYCLICS LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-20130273030-A1 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | PHARMACYCLICS, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130202611-A1 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | PHARMACYCLICS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130178483-A1 | Methods and Compositions for Inhibition of Bone Resorption | PHARMACYCLICS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8435976-B2 | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE (CH) | 2013-05-07 | — | — | US | disclosed |
| US-20120183535-A1 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | PHARMACYCLICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120087915-A1 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | PHARMACYCLICS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120071497-A1 | METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110059961-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-03-10 | — | — | US | disclosed |
| US-20100190861-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2010-07-29 | — | — | US | disclosed |
| US-20070203111-A1 | Cycloalkylamines as monoamine reuptake inhibitors | SEPRACOR INC. (US) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071497-A1 | METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, BCL6, BCL6B | ALDH1A1 3582/4885LMNA 2826/4885KDM4E 1288/4885 |
| US-11718630-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | ALDH1A1 2792/4885LMNA 2600/4885KDM4E 3032/4885 |
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | ALDH1A1 1817/4885LMNA 4048/4885KDM4E 1725/4885 |
| US-20230242544-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | ALDH1A1 1817/4885LMNA 3720/4885KDM4E 2736/4885 |
| US-20070203111-A1 | Cycloalkylamines as monoamine reuptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | ALDH1A1 1474/4885LMNA 2549/4885KDM4E 860/4885 |
| US-20100190861-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | ALDH1A1 1474/4885LMNA 2549/4885KDM4E 860/4885 |
| US-11857603-B2 | PTH compounds with low peak-to-trough ratios | PTH1R, PTMS, FGF23 | ALDH1A1 4537/4885LMNA 3162/4885KDM4E 3809/4885 |
| US-20130178483-A1 | Methods and Compositions for Inhibition of Bone Resorption | BTK, CTTN, BMX | ALDH1A1 4755/4885LMNA 2321/4885KDM4E 923/4885 |
| US-20230248730-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | BTK, LYN, SYK | ALDH1A1 3452/4885LMNA 4363/4885KDM4E 2333/4885 |
| US-11672803-B2 | Use of inhibitors of Brutons tyrosine kinase (Btk) | BTK, LYN, SYK | ALDH1A1 3452/4885LMNA 4363/4885KDM4E 2333/4885 |
| US-20240067656-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | ALDH1A1 2792/4885LMNA 2600/4885KDM4E 3032/4885 |
| US-20130273030-A1 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | BTK, SYK, LYN | ALDH1A1 3331/4885LMNA 4440/4885KDM4E 2459/4885 |
| US-20130202611-A1 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | BTK, SYK, LYN | ALDH1A1 3331/4885LMNA 4440/4885KDM4E 2459/4885 |
| US-20110059961-A1 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM3, PIM2 | ALDH1A1 1066/4885LMNA 464/4885KDM4E 309/4885 |
| US-20120087915-A1 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | BTK, SYK, LYN | ALDH1A1 3331/4885LMNA 4440/4885KDM4E 2459/4885 |
| US-20120183535-A1 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | BTK, SYK, LYN | ALDH1A1 3331/4885LMNA 4440/4885KDM4E 2459/4885 |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | ALDH1A1 1158/4885LMNA 3767/4885KDM4E 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.